Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball, A B, K B Gordon, S Fakharzadeh, N Yeilding, P O Szapary, B Schenkel, C Guzzo, S Li, and K A Papp. 2012. “Long-Term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis: Results from the PHOENIX 1 Trial through up to 3 Years.”. The British Journal of Dermatology 166 (4): 861-72.